Analysis on Efficacy of CIK Cells in Advanced Malignant Tumors

Objective To study the clinical efficacy of adoptive immunotherapy with autologous CIK cells in patients with advanced malignant tumors. Methods Peripheral blood mononuclear cells(PBMCs) of 34 patients with advanced malignant tumors were isolated,and then were incubated in vitro with IFN-γ,IL-2 and anti-CD3 monoclonal antibody.The total number of CIK cells per patient expanded about 4.5～6×109,and then were transfused back to the patients with three times.The changes of tumor weight,immunity indexes,tumor markers,clinical symptoms,and toxicity in the patients were observed before and after CIK cells being transfused back. Results After being treated with CIK cells,the CD3+,CD4+,CD4+/CD8+ and NK cells(CD16,CD56) of 34 patients were increased significantly(P0.05),but CD8+ was decreased at the same time.The total efficiency(CR+PR+MR) was 79.4%.Among 24 patients with increasing serum CEA level,19 showed a reduction.In 8 patients with increasing serum CA125 level,6 showed a reduction.4 patients with increasing serum CA199 level showed a reduction entirely.The clinical symptoms of the treated patients were improved with little toxicity. Conclusions The adoptive immunotherapy with CIK cells can significantly enhance cellular immune function and improve the quality of life and clinical symptoms for the patients with advanced malignant tumors.